Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Florida for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Florida only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Florida (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Christopher Lobo (NPI 1073571949)

Field	Value
Entity Type	Individual
Organization	Christopher Lobo
Address	22395 Edgewater Dr
City	Port Charlotte
State	FL
ZIP	33980
Taxonomy	Medical Oncology Physician
NPI Enumerated	May 2, 2006

Payer Source	Total Paid
Medicare	$6.1M
Medicaid	$0

Key Findings

CHRISTOPHER LOBO is a Medical Oncology Physician in PORT CHARLOTTE, FL with an NPI enumerated on 2006-05-02 (~20 years ago). His billing profile is dominated by Medicare with Total Medicare revenue: $6.1M and no Medicaid billing on file, indicating an effectively single-payer Medicare practice footprint rather than a mixed Medicare/Medicaid revenue stream.

Revenue concentration is high: the precomputed top 3 Medicare codes account for 55.8% of total Medicare revenue, driven by J9271 ($1.6M, 27.2%), J9144 ($916.6K, 15.4%), and J9299 ($785.3K, 13.2%). This level of concentration around three high-cost biologic/immunotherapy codes signals that a majority of billing dollars flow from expensive infusion drugs rather than routine office visits alone.

The procedure and drug mix indicates an infusion-centered oncology practice focused on high-cost monoclonal antibodies and immune checkpoint inhibitors. High-revenue drug codes include J9271 (pembrolizumab), J9144 (daratumumab), J9299 (nivolumab) and J9173 (durvalumab, $680.5K), and the presence of chemotherapy administration codes such as 96413 ($128K) and add-on 96417 ($17.6K) supports routine outpatient infusion services.

Competitive standing on specific immunotherapy codes is strong: J9271 ranks #42 of 1841 providers nationally (98th percentile; notably above typical national volume) and J9144 ranks #32 of 615 (94th percentile; notably above typical national volume), while J9173 ranks #3 of 53 (96th percentile; notably above typical national volume). At the same time, some large revenue drugs such as J9299 rank #57 of 505 (89th percentile; typical, unremarkable volume), so dominance is concentrated in select agents rather than uniformly across all immunotherapies.

Service-line operational intensity is reflected in very high claim counts for several codes: J9271 37.6K claims, J9144 24.1K claims and J9299 32.7K claims, which together with frequent administration codes (96365, 96375, G0498) point to high throughput infusion operations. Office E/M volume is also notable: 99214 shows 2.9K claims and $270.9K revenue (4.6% of Medicare revenue) and is flagged as an extreme outlier nationally, indicating a heavy clinic visit load to manage these patients.

Multiple codes are flagged as statistical outliers or extreme outliers, reinforcing the picture of above-average intensity: 99214 ranks #314 of 479517 (100th percentile; extreme outlier, far above typical national volume), 96413 ranks #20 of 7514 (100th percentile; extreme outlier, far above typical national volume), 96375 ranks #20 of 5191 (100th percentile; extreme outlier, far above typical national volume), and G0498 ranks #14 of 896 (98th percentile; extreme outlier, far above typical national volume). These labels suggest operational scale and billing patterns that sit well above national norms for infusion and visit activity.

The absence of Medicaid billing (none below — this provider has no Medicaid billing on file) concentrates payer risk and contracting exposure on Medicare, which may simplify payer relationships but increases sensitivity to Medicare payment policy changes. Given Total Medicare revenue: $6.1M and no Medicaid revenue reported, any strategic or reimbursement shifts in Medicare could have outsized impact on this provider's revenue base.

Beyond drug administration, the mix includes supportive care and ancillary services such as J0897 (denosumab, $389.9K, 6.6% of revenue) and lab services like 85025 (CBC, $40K), indicating a comprehensive oncology outpatient service model that bundles drug infusion with supportive medications and routine monitoring. Together these signals portray a high-volume, clinic-based oncology practice with concentrated revenue exposure to a handful of expensive biologic agents.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

73 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	37,600	$40	$1.6M
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	24,120	$40	$916.6K
J9299	Injection, nivolumab, 1 mg	32,720	$20	$785.3K
J9173	Injection, durvalumab, 10 mg	10,980	$60	$680.5K
J0897	Injection, denosumab, 1 mg	20,520	$20	$389.9K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	9,790	$40	$352.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	2,850	$100	$270.9K
J2182	Injection, mepolizumab, 1 mg	8,100	$20	$186.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,320	$100	$128K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	2,980	$30	$101.2K

Showing 1–10 of 73

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 73 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Florida Distribution

Christopher Lobo — 13 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Florida

Full comparison — all codes billed, vs. state median

73 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	13	210	16,100	$40	$802.7K
J9299	12	70	15,580	$20	$423.9K
J9144	4	80	9,000	$40	$410.6K
J0129	115	130	9,350	$30	$386.8K
J9173	2	10	2,600	$60	$275.1K
J2357	48	50	6,090	$30	$226K
J2182	12	20	8,800	$20	$218.7K
J1569	13	130	4,080	$40	$176.2K
J0897	46	1,060	3,290	$20	$106.5K
J1449	20	40	3,560	$30	$99.2K

Showing 1–10 of 73

Related Providers

Other providers that share a Tax Identification Number (TIN) with Christopher Lobo, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Florida Cancer Specialists & Research Institute, LLC	FL	Medical Oncology Physician	$0	$63.5M
Wilfredo Blasini	FL	Clinical Pathology Physician	$16.9M	$307.9K
Ryan Olson	FL	Anatomic Pathology & Clinical Pathology Physician	$12.8M	$80
Robert Mcdonald	AZ	Diagnostic Radiology Physician	$7.5M	$0
Syed Zafar	FL	Medical Oncology Physician	$6M	$0
Ronald Goodwich	FL	Nuclear Medicine Physician	$5.7M	$0
Steven Newman	FL	Medical Oncology Physician	$5.7M	$0
Andrew Lipman	FL	Medical Oncology Physician	$5.6M	$0
Vijay Patel	FL	Medical Oncology Physician	$4.8M	$0
Jay Wang	FL	Medical Oncology Physician	$4.5M	$0

Nearby Providers

Other providers in the same ZIP code as Christopher Lobo, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ambitrans Medical Transport , Inc.	FL	Land Ambulance	$3.9M	$1.4M
Ivor Percent	FL	Medical Oncology Physician	$3.1M	$0
Vance Wright-browne	FL	Medical Oncology Physician	$2.9M	$0
Arsh Singh	FL	Medical Oncology Physician	$2.4M	$0
Arthur Ballard	FL	Diagnostic Radiology Physician	$671.4K	$0
Lohaliz Bobe	FL	Pulmonary Disease Physician	$474.9K	$0
Jaime Cancel	FL	Pulmonary Disease Physician	$452.6K	$3K
Carlos Maas	FL	Pulmonary Disease Physician	$438.4K	$0
Maria Compton	FL	Otolaryngology/Facial Plastic Surgery Physician	$302.8K	$0
Ramon Gil	FL	Specialist	$224K	$0

Christopher Lobo — Billing Profile & Reimbursement Data

Sign up for Christopher Lobo — Billing Profile & Reimbursement Data policy alerts

Christopher Lobo — Billing Profile & Reimbursement Data

Sign up for Christopher Lobo — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References